Pulsing its global MDoutlook network of over 62,000 cancer treaters, Arcas is the first organization presenting the clinical impact of new data presented at ASCO.
Focusing on key new data presented in Melanoma, Lung Cancer, Renal Cell Carcinoma, Prostate Cancer, Colorectal Cancer and Hepatocellular Carcinoma, we are distributing the results in 4 reports. Based on a total response of more than 400 cancer treaters from 22 countries, we are proud to present our analysis on the first three disease areas:
* MDoutlook ASCO 2012 QP – NSCLC+RCC
* MDoutlook ASCO 2012 QP – Melanoma
MDoutlook activities are predicated on 3 critical principles: 1) Relevant and accurate insight directly from pre-validated treaters; 2) Robust coverage and 3) Rapid response. Insight is presented in reports that can be shared directly with senior management, and intelligence is enhanced by the review and feedback from key ThoughtLeaders in each disease covered.
We continue our collaboration with our friends at Oncology Business Review (OBR) for distribution of this report; their Editor’s Blog has a copy of the results.
If you have any questions or would like to discuss how MDoutlook can support your oncology intelligence needs, please contact me directly.
President, The Arcas Group